ClinVar

Description

The RYR1 c.7025A>G variant is predicted to result in the amino acid substitution p.Asn2342Ser. This variant has been reported in several individuals with malignant hyperthermia (MH) (see, for example, Marchant et al. 2004. PubMed ID: 15221887; Miller et al. 2018. PubMed ID: 30236257). However, some individuals with MH who carry this variant also had another causative RYR1 variant (Carpenter et al. 2009. PubMed ID: 19825159; Supplementary File 1, Knuiman et al. 2019. PubMed ID: 30788618). In one family, this variant was detected in trans with a clear dominant, pathogenic MH variant in the proband and also observed in the proband’s three children, at least two of whom had negative in vitro contracture testing (Tammaro et al. 2011. PubMed ID: 20681998). This variant is reported in 0.21% of alleles in individuals of South Asian descent in gnomAD v2, which is much more frequent (~10 times) than the most frequent, well-characterized MH pathogenic variants. In the updated gnomAD v4, three individuals homozygous for this variant were observed. The ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel interprets this variant as likely benign in regard to autosomal dominant malignant hyperthermia susceptibility (https://www.ncbi.nlm.nih.gov/clinvar/variation/133175/). This variant has also been reported with or without a second RYR1 variant in individuals with RYR1-related myopathy (Snoeck et al. 2015. PubMed ID: 25960145; Garibaldi et al. 2019. PubMed ID: 30611313; Fusto et al. 2022. PubMed ID: 35428369). This variant was found in a parent with congenital myopathy; however, it was not found in the individual’s similarly affected daughter, and a TPM3 variant was found in both individuals (Klein et al. 2012. PubMed ID: 22473935). In summary, this variant is likely too common to be a primary cause of RYR1-related disorders and the clinical significance of this variant is uncertain due to conflicting evidence.